Ravulizumab-cwvz (Ultomiris)

Number: 0946

Policy

Note: Requires Precertification.

Precertification of ravulizumab-cwvz (Ultomiris) is required of all Aetna participating providers and members in applicable plan designs.  For precertification of ravulizumab-cwvz, call (866) 752-7021, or fax (866) 267-3277.

Note: Site of Care Utilization Management Policy applies.  For information on site of service for Ultomiris infusions, see Utilization Management Policy on Site of Care for Specialty Drug Infusion.

  1. Aetna considers ravulizumab-cwvz (Ultomiris) medically necessary for the treatment of the following indications when all of the following criteria are met:

    1. Paroxysmal Nocturnal Hemoglobinuria (PNH)

      1. The diagnosis of PNH was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) as demonstrated by either of the following:

        1. At least 5% PNH cells; or
        2. At least 51% of GPI deficient poly-morphonuclear cells; and
      2. Flow cytometry is used to demonstrate GPI-APs deficiency.

    2. Atypical hemolytic uremic syndrome (aHUS) not caused by Shiga toxin

      1. Absence of Shiga toxin; and
      2. ADAMTS 13 activity level above 5%.
  2. Aetna considers continuation of ravulizumab-cwvz (Ultomiris) medically necessary for treatment of the following indications when criteria are met:

    1. Paroxysmal nocturnal hemoglobinuria

      For members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., improvement in hemoglobin levels, normalization of lactate dehydrogenase [LDH] levels). 

    2. Atypical hemolytic uremic syndrome (aHUS)

      For members requesting requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., normalization of lactate dehydrogenase (LDH) levels, platelet counts).

  3. Aetna considers concurrent use of ravulizumab-cwvz and eculizumab experimental and investigational because the safety and efficacy of this combination has not been established.

  4. Aetna considers ravulizumab-cwvz experimental and investigational when criteria are not met and for all other indications including the following (not an all-inclusive list) because the safety and effectiveness for these indications has not been established:

    • Amyotrophic lateral sclerosis
    • Aplastic anemia
    • Myasthenia gravis
    • Neuromyelitis optica

See also CPB 0807 - Eculizumab (Soliris).

Dosing Recommendations

Ravulizumab-cwvz is available as Ultomiris in 300 mg/30mL (10 mg/mL), 300 mg/3mL (100 mg/mL), and 1,100 mg/11mL (100 mg/mL) in a single-dose vial for intravenous (IV) infusion.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • The recommended dosing regimen for adults (18 years of age and older) with PNH weighing 40 kg or greater, consists of a loading dose followed by maintenance dosing, administered by intravenous (IV) infusion. Administer the doses based on the person’s body weight, as shown in Table 1
  • Starting 2 weeks after the loading dose administration, begin maintenance doses at a once every 8-week interval. The dosing schedule is allowed to occasionally vary within 7 days of the scheduled infusion day (except for the first maintenance dose of Ultomiris) but the subsequent dose should be administered according to the original schedule.
  • For persons switching from eculizumab to Ultomiris, administer the loading dose of Ultomiris 2 weeks after the last eculizumab infusion, and then administer maintenance doses once every 8 weeks or every 4 weeks (depending on body weight), starting 2 weeks after loading dose administration.

Table 1: Ravulizumab-cwvz (Ultomiris) Weight-Based Dosing Regimen for PNH
Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg)
greater than or equal to 40 to less than 60 2,400 3,000
greater than or equal to 60 to less than 100 2,700 3,300
greater than or equal to 100 3,000 3,600

Atypical Hemolytic Uremic Syndrome (aHUS)

The recommended dosing regimen in adult and pediatric persons 1 month of age and older with aHUS weighing 5 kg or greater, consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. Administer the doses based on the person's body weight, as shown in Table 2. Starting 2 weeks after the loading dose administration, begin maintenance doses once every 8 weeks or every 4 weeks (depending on body weight).

Table 2: Ravulizumab-cwvz (Ultomiris) Weight-Based Dosing Regimen for aHUS
Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) and Dosing Interval
greater than or equal to 5 to less than 10 600 300 Every 4 weeks
greater than or equal to 10 to less than 20 600 600
greater than or equal to 20 to less than 30 900 2,100 Every 8 weeks
greater than or equal to 30 to less than 40 1,200 2,700
greater than or equal to 40 to less than 60 2,400 3,000
greater than or equal to 60 to less than 100 2,700 3,300
greater than or equal to 100 3,000 3,600

Source: Alexion Pharma, 2020

Background

U.S. Food and Drug Administration (FDA)-Approved Indications

  • Ultomiris is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
  • Ultomiris is indicated for the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
  • Limitations of Use: Ultomiris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Ultomiris (ravulizumab-cwvz), a complement inhibitor, is a humanized monoclonal antibody (mAb). Ultomiris (ravulizumab-cwvz) binds specifically to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. Ultromiris inhibits terminal complement-mediated intravascular hemolysis in persons with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) (Alexion Pharma, 2018a, Alexion Pharma, 2018b).

Black Box Warnings:

  • Life‐threatening and fatal meningococcal infections have occurred in patients treated with ravulizumab (Ultomiris). Meningococcal infection may become rapidly life‐threatening or fatal if not recognized and treated early.
  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of ravulizumab (Ultomiris)), unless the risks of delaying ravulizumab (Ultomiris) therapy outweigh the risk of developing a meningococcal infection.
  • Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Ultomiris is contraindicated in persons with unresolved Neisseria Meningitidis infection. The most frequent adverse reaction (greater than 10 percent) were upper respiratory infection and headache (Alexion Pharma, 2020).

Due to the risk of meningococcal infections, Ultomiris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Ultomiris REMS, prescribers must enroll in the program (Alexion Pharma, 2020).

Paroxysmal Nocturnal Hemoglobinuria (PNH)

On December 21, 2018, the FDA approved Ultomiris (ravulizumab-cwvz) (Alexion Pharmaceuticals, Inc) injection, a long-acting C5 complement inhibitor, for the treatment of adult patients with PNH. FDA approval was based on the results of two Phase 3 studies (301 and 302 study) (Alexion Pharma, 2018a; FDA, 2018).

The 301 study was a phase 3, open-label trial which assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor-naive adults with paroxysmal nocturnal hemoglobinuria (PNH).  A total of 246 patients with lactate dehydrogenase (LDH) ≥1.5 times the upper limit of normal, confirmation of at least 5% PNH cells per flow cytometry, and with at least one PNH symptom were randomized 1:1 to receive ravulizumab or eculizumab for 183 days. Primary efficacy endpoints included proportion of patients remaining transfusion-free, and LDH normalization. Secondary endpoints included percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, proportion of patients with breakthrough hemolysis, stabilized hemoglobin, and change in serum free C5. The authors found that ravulizumab was noninferior to eculizumab for both co-primary and all key secondary endpoints (Pinf < .0001): transfusion avoidance (73.6% versus 66.1%; difference of 6.8% [95% confidence interval (CI), -4.66, 18.14]), LDH normalization (53.6% versus 49.4%, odds ratio [1.19 (0.80, 1.77)]), percent reduction in LDH (-76.8% versus -76.0%; difference [95% CI], -0.83% [-5.21, 3.56]), change in FACIT-Fatigue score (7.07 versus 6.40; difference [95% CI], 0.67 [-1.21, 2.55]), breakthrough hemolysis (4.0% versus 10.7%; difference [95% CI], -6.7% [-14.21, 0.18]), and stabilized hemoglobin (68.0% versus 64.5%; difference [95% CI], 2.9 [-8.80, 14.64]). The safety and tolerability of ravulizumab and eculizumab were similar, and no meningococcal infections occurred. The authors concluded that ravulizumab given every 8 weeks achieved noninferiority compared with eculizumab given every 2 weeks for all efficacy endpoints, and had similar safety profiles (Lee et al., 2019) ClinicalTrials.gov #NCT02946463.

ClinicalTrials.gov Identifier: NCT02946463 study inclusion criteria included the following:

  • Male or female ≥ 18 years of age
  • PNH diagnosis confirmed by documented by high-sensitivity flow cytometry (confirmation of at least 5% PNH cells)
  • Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of Screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia (hemoglobin <10 g/dL), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of pRBC transfusion due to PNH
  • LDH level ≥ 1.5 × ULN at screening
  • Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment
  • Female patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210
  • Willing and able to give written informed consent and comply with study visit schedule.

Kulasekararaj et al (2019) stated that ravulizumab was found to be noninferior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were previously treated with eculizumab and switched to ravulizumab. The authors conducted a phase 3, open-label, multicenter study (302 study) which assessed noninferiority of ravulizumab to eculizumab in clinically stable PNH patients during previous eculizumab therapy.  A total of 195 PNH patients on labeled-dose (900 mg every 2 weeks) eculizumab for greater than 6 months were randomly assigned 1:1 to switch to ravulizumab (n = 97) or continue eculizumab (n = 98). Primary efficacy endpoint was percentage change in lactate dehydrogenase (LDH) from baseline to day 183. Key secondary endpoints included proportion of patients with breakthrough hemolysis, change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, transfusion avoidance, and stabilized hemoglobin. The authors found that In 191 patients completing 183 days of treatment, ravulizumab was noninferior to eculizumab (Pinf<.0006 for all endpoints), including percentage change in LDH (p = 0.058 for superiority), breakthrough hemolysis (difference, 5.1 [95% CI: -8.89 to 18.99]), change in FACIT-Fatigue score (difference, 1.47 [95% CI: -0.21 to 3.15]), transfusion avoidance (difference of 5.5 [95% CI: -4.27 to 15.68]), and stabilized hemoglobin (difference, 1.4 [95% CI: -10.41 to 13.31]). The most frequently reported adverse event was headache (26.8%, ravulizumab; 17.3%, eculizumab). No meningococcal infections or discontinuations due to adverse events occurred. The authors concluded that patients with PNH may be safely and effectively switched from labeled-dose eculizumab administered every 2 weeks to ravulizumab administered every 8 weeks. (Funded by Alexion Pharmaceuticals, Inc., ClinicalTrials.gov: NCT03056040).

ClinicalTrials.gov Identifier: NCT03056040 study inclusion criteria included the following:

  • Male or female ≥18 years of age
  • Treated with eculizumab for PNH for at least 6 months prior to Day 1
  • LDH level ≤ 1.5 × ULN at screening
  • PNH diagnosis confirmed by documented by high-sensitivity flow cytometry
  • Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment
  • Female patients of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ALXN1210
  • Willing and able to give written informed consent and comply with study visit schedule.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, progressive, life-threatening, multi-systemic clonal blood disorder which leads to impaired production and premature death of blood cells. It is estimated to affect between 1 and 5 per million of people. Although this disorder can affect leukocytes (white blood cells) and thrombocytes (platelets), it has specifically been associated with the abnormal development and destruction of erythrocytes (red blood cells), known as PNH cells, which are deficient in a protein that protects RBCs from being destroyed by a component of the body’s immune system, known as the complement system. People with PNH have sudden, recurring episodes of hemolysis, which can present as hemoglobinuria and anemia. In addition to hemolysis, those with PNH are susceptible to developing thrombosis, pulmonary hypertension, and damage to organs such as the brain, liver, gastro-intestinal system, and kidneys. Individuals may also experience a variety of symptoms that can interfere with quality of life including: abdominal pain, difficulty swallowing, poor physical function, shortness of breath, erectile dysfunction, and debilitating fatigue. The specific symptoms of PNH vary greatly from one person to another and affected individuals usually do not exhibit all of the symptoms associated with the disorder. PNH can occur at any age, although it is most often diagnosed in young adulthood (Alexion Pharma, 2018s; Besa, 2018; FDA, 2018; NIH/NLM, 2018; NORD, 2016).

PNH originates from a somatic mutation of the X-linked phosphatidylinositol glycan class A (PIGA) gene. In PNH, this mutation results in hematopoietic stem cells that are deficient in glycosyl-phosphatidylinositol anchor protein (GPI-AP), which is necessary to protect cells from complement-mediated lysis. The absence of these complement-regulating surface proteins results in uncontrolled amplification of the complement system. This leads to intravascular destruction of the RBC membrane of these PNH cells which results in low RBC counts that causes the symptoms of PNH, and can lead to disability and premature death (Besa, 2018; Brodsky, 2017a).

Flow cytometry is the most useful and accepted method to confirm the diagnosis of PNH. Flow cytometry measures the percentage of cells that are deficient in the GPI-APs and identifies discrete populations with different degrees of deficiency. Because of the missing GPI-APs, RBCs and other cells in persons with PNH lack DAF (CD55) and MIRL (CD59), which regulate complement. The diagnosis of PNH is made by demonstrating that peripheral blood cells are deficient in GPI-linked proteins, in the appropriate clinical setting (e.g., Coombs-negative hemolytic anemia). Absence or reduced expression of both CD59 and CD55 on RBCs is diagnostic of PNH. Since different blood cell lineages display different combinations of GPI-linked proteins, and some proteins bind to cell surfaces via both GPI-linked and GPI-independent mechanisms, it is recommended that at least two independent flow cytometry reagents be used on at least two cell lineages (e.g., RBCs and WBCs) to establish the diagnosis of PNH. Bone marrow examination is not required for the diagnosis of PNH, but is recommended in patients with significant pancytopenia (Besa, 2018; Brodsky, 2017b).

“Complement-mediated intravascular hemolysis is the most prominent clinical feature in classical PNH. Evidence of intravascular hemolysis includes the presence of free hemoglobin in the serum or urine, decreased serum haptoglobin, and elevated serum lactate dehydrogenase (LDH). Elevation of the LDH level to >1.5 times the upper limit of normal can be seen with as few as 3 percent PNH RBCs. Hemolysis in PNH is not exclusively nocturnal, and may be seen continuously by sensitive methods including the serum haptoglobin and LDH” (Brodsky, 2017a).

Historically, treatment of PNH had largely been supportive care measures including anti-coagulation, folic acid supplementation, hydration, and red blood cell (RBC) transfusion.  According to Besa (2018), the “ideal treatment is to replace the defective hematopoietic stem cell with a normal equivalent by stem cell transplantation; however, this is not realistic for many patients, because stem cell transplantation requires a histocompatible donor and is associated with significant morbidity and mortality. This form of treatment is reserved for severe cases of PNH with aplastic anemia or transformation to leukemia, both of which are life-threatening complications.” In 2007, the U.S. Food and Drug Administration [FDA] approved a complement inhibitor called eculizumab (Soliris, Alexion Pharmaceuticals, Inc.) for the treatment of patients with PNH to reduce hemolysis.  Eculizumab is a recombinant humanized monoclonal antibody that works by binding to complement protein C5, inhibiting its enzymatic cleavage, blocking formation of the terminal complement complex, and thus preventing red cell lysis; however, eculizumab requires maintenance administration dosing every 2 weeks. Therefore, the development of a longer-acting infusion may decrease the burden of frequent dosing, without compromising safety and efficacy (Alexion Pharma, 2018a; Besa, 2018; Brodsky, 2018; FDA, 2018). Ravulizumab was engineered from eculizumab to have a substantially longer terminal half-life, permitting longer dosing intervals for patients with PNH (Roth et al. 2018).

Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical hemolytic uremic syndrome (aHUS) is a rare disease that is characterized by hemolytic anemia, thrombrocytopenia and kidney failure. This condition causes inflammation and the formation of blood clots in small blood vessels throughout the body (thrombotic microangiopathy [TMA]) mediated by chronic, uncontrolled activation of the complement system. TMA consists of reduced platelet count (thrombocytopenia), hemolytic anemia (as a result of hemolysis [destruction of red blood cells]) and acute kidney injury (AKI). If left untreated, significant proportions of adults (46 percent) and children (16 percent) can progress to end-stage renal disease (ESRD) or die during first clinical manifestations of aHUS despite supportive care, including plasma exchange or plasma infusion. One year following clinical manifestations, 56 percent of adults and 29 percent of children can progress to ESRD or die, if left untreated (Alexion Pharma, 2019a; NIH, 2017; NORD 2016).

On October 18, 2019, the U.S. Food and Drug Administration (FDA) approved Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) for adult and pediatric (one month of age and older) patients. The FDA approval is based on data from two global, single-arm open-label studies of Ultomiris – one in adults and one in children with aHUS. The pediatric study is ongoing and a total of 14 out of 16 children were enrolled and included in the interim analysis. Efficacy evaluation of Complete TMA Response was defined by hematologic normalization parameters (platelet count and LDH) and improved kidney function (as measured by 25 percent and greater improvement in serum creatinine from baseline). In the initial 26-week treatment periods, 54 percent of adults and 71 percent (interim data) of children demonstrated Complete TMA Response. Study outcomes showed that treatment with Ultomiris resulted in reduced thrombocytopenia (low blood platelet count) in 84 percent of adults and 93 percent of children, reduced hemolysis in 77 percent of adults and 86 percent of children, and improved kidney function in 59 percent of adults and 79 percent (interim data) of children (for patients on dialysis at enrollment, baseline was established after they had come off dialysis).The most frequently observed adverse reactions reported in these studies were upper respiratory tract infection, diarrhea, nausea, vomiting, headache, hypertension and pyrexia. Serious meningococcal infections have occurred in patients treated with Ultomiris. To minimize the risk for patients, specific risk-mitigation plans, including a REMS program, have been established for Ultomiris (Alexion Pharma, 2019a).

The adult study [ALXN1210-aHUS-311; NCT02949128] was conducted in patients who were naïve to complement inhibitor treatment prior to study entry. The study consisted of a 26-week Initial Evaluation Period and patients were allowed to enter an extension period for up to 4.5 years. A total of 56 adult patients with aHUS were evaluated for efficacy. Ninety-three percent of patients had extrarenal signs (cardiovascular, pulmonary, central nervous system, gastrointestinal, skin, skeletal muscle) or symptoms of aHUS at baseline. At baseline, 71.4% (n = 40) of patients had Stage 5 chronic kidney disease (CKD). Fourteen percent had a medical history of kidney transplant and 51.8% were on dialysis at study entry. Eight patients entered the study with evidence of TMA for > 3 days after childbirth (ie, postpartum). One additional patient had a Complete TMA Response that was confirmed after the 26-week Initial Evaluation Period. Complete TMA Response was achieved at a median time of 86 days (range: 7 to 169 days). The median duration of Complete TMA Response was 7.97 months (range: 2.52 to 16.69 months). All responses were maintained through all available follow-up. Other endpoints included platelet count change from baseline, dialysis requirement, and renal function as evaluated by estimated glomerular filtration rate (eGFR). An increase in mean platelet count was observed after commencement of Ultomiris at Day 8 and remaining above 227 × 109 /L at all subsequent visits in the Initial Evaluation Period (26 weeks). Renal function, as measured by eGFR, was improved or maintained during therapy. The mean eGFR increased from 15.86 (14.82) at baseline to 51.83 (39.16) by 26 weeks. In patients with Complete TMA Response, renal function continued to improve after the Complete TMA Response was achieved. Seventeen of the 29 patients (59%) who required dialysis at study entry discontinued dialysis by the end of the available follow-up and 6 of 27 (22%) patients were off dialysis at baseline were on dialysis at last available follow-up (Alexion Pharma 2019b).

The Pediatric Study [ALXN1210-aHUS-312; NCT03131219] is a 26-week ongoing, multicenter, single-arm study conducted in 16 pediatric patients. A total of 14 eculizumab-naïve patients with documented diagnosis of aHUS were enrolled and included in this interim analysis. The median age at the time of first infusion was 5.2 years. The overall mean weight at Baseline was 19.8 kg; half of the patients were in the baseline weight category ≥ 10 to < 20 kg. The majority of patients (71%) had pretreatment extra-renal signs (cardiovascular, pulmonary, central nervous system, gastrointestinal, skin, skeletal muscle) or symptoms of aHUS at baseline. At baseline, 35.7% (n = 5) of patients had a CKD Stage 5. Seven percent had history of prior kidney transplant and 35.7% were on dialysis at study entry. Efficacy evaluation was based upon Complete TMA Response during the 26-week Initial Evaluation Period, as evidenced by normalization of hematological parameters (platelet count and LDH) and ≥ 25% improvement in serum creatinine from baseline. Patients had to meet all Complete TMA Response criteria at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between. Complete TMA Response was observed in 10 of the 14 patients (71%) during the 26-week Initial Evaluation Period. Complete TMA Response during the Initial Evaluation Period was achieved at a median time of 30 days. The median duration of Complete TMA Response was 5.08 months. All responses were maintained through all available follow-up. Other endpoints included platelet count change from baseline, dialysis requirement, and renal function as evaluated by eGFR. An increase in mean platelet count was observed after commencement of Ultomiris, increasing from 60.50 × 109 /L at baseline to 296.67 × 109 /L at Day 8 and remained above 296 × 109 /L at all subsequent visits in the Initial Evaluation Period (26 weeks). The mean eGFR increased from 28.4 at baseline to 108.0 by 26 weeks. Four of the 5 patients who required dialysis at study entry were able to discontinue dialysis after the first month in study and for the duration of treatment. No patient started dialysis during the study (Alexion Pharma, 2019b).

Other Indications

Amyotrophic Lateral Sclerosis

Chen (2020) noted that amyotrophic lateral sclerosis (ALS) is a devastating, fatal neuromuscular disease.  Most patients die within 2 to 5 years of diagnosis.  The disease stems from death of upper and lower motor neurons leading to degeneration of motor pathways and the paralytic effects of the disease.  Two drugs, riluzole and edaravone, are currently FDA-approved for the treatment of ALS, and each provides modest benefits in mortality and/or function.  Recent developments in the understanding of the underlying pathophysiologic processes that contribute to ALS have led to the development of numerous investigational therapies, with several now in phase-III clinical trials.  The author highlighted the oral tyrosine kinase inhibitor masitinib; the antisense drug tofersen; the humanized monoclonal antibody C5 complement inhibitor ravulizumab-cwvz; and mesenchymal stem cell (MSC)-neurotrophic factor (NTF) cells, a proprietary platform that induces autologous bone marrow-derived MSCs to secrete high levels of NTFs.

Aplastic Anemia (AA) with Underlying PNH

PNH defect have been detected by flow cytometry in approximately half of persons with AA (Schrier, 2017). An UpToDate review on “Treatment of aplastic anemia in adults” (Shrier, 2018) states that “there is substantial overlap between AA and PNH. Patients with AA have an increased risk of developing PNH, and patients with PNH have an increased risk of developing AA. Therapy for AA in patients with a PNH clone is similar to that for patients without PNH. For those who undergo HCT, this may result in elimination of the PNH clone.” Furthermore, complement inhibitors (i.e., eculizumab and ravulizumab-cwvz) were not listed as a treatment option. Persons who meet criteria for severe aplastic anemia (AA) with a PNH clone (AA/PNH) should be managed with either allogeneic HCT or immunosuppressive therapy for AA (Brodsky, 2018).

Neuromyelitis Optica

Duchow and colleagues (2020) stated that evidence-based therapeutic options for patients with neuromyelitis optica spectrum disorders (NMOSD) are beginning to enter the market; where previously, there was only the exclusive use of empiric and off-label immunosuppressants in this rare and devastating central nervous system (CNS) autoimmune disease.  In accordance to expanding pathogenetic insights, drugs in phase-II and phase-III clinical trials are presented in the context of the current treatment situation for acute attacks and immuno-preventative strategies in NMOSD.  Some such drugs are the 2019-approved complement inhibitor eculizumab, other compounds in late development include its modified successor ravulizumab, IL-6 receptor antibody satralizumab, CD19 targeting antibody inebilizumab and the TACI-Fc fusion protein telitacicept.  The authors concluded that moving from broad immunosuppression to tailored treatment strategies, the prospects for efficient NMOSD therapy are positive.  For the first time in this disease, class I treatment evidence is available, but long-term data are needed to confirm the overall promising findings of the compounds close to approval.  While drug development still centers around AQP4 antibody sero-positive patients, current and future research requires consideration of possible diverging treatment demands for the smaller group of sero-negative patients and patients with presence of MOG antibodies.

Appendix

Major Adverse Vascular Events (MAVE)

Venous thrombosis

  • Acute peripheral vascular occlusion,
  • Clinically apparent distal embolization (e.g., lower extremity ulceration, tissue necrosis, gangrene, limb amputation or other end-organ damage)
  • Deep vein thrombosis,
  • Hepatic/portal vein thrombosis,
  • Mesenteric/splenic vein thrombosis,
  • Pulmonary embolus, 
  • Renal vein thrombosis,
  • Thrombophlebitis

Arterial thrombosis

  • Acute peripheral vascular occlusion
  • Cerebrovascular accident,
  • Myocardial infarction,
  • Transient ischemic attack,
  • Unstable angina

Source: Hillmen 2007, 2019.

Criteria for Diagnosis of Severe Aplastic Anemia

The diagnostic criteria for severe aplastic anemia are:

  • Bone marrow cellularity less than 25 percent (or cellularity 25 to 50 percent if less than 30 percent of residual cells are hematopoietic); and
  • At least 2 among the following:
     
    • Peripheral blood absolute reticulocyte count less than 20,000 per microL (<20 × 10⁹/L )
    • Peripheral blood platelet count less than 20,000 per microL (<20 × 10⁹/L)
    • Peripheral blood absolute neutrophil count (ANC) less than 500 per microL (<0.5 × 10⁹/L).

Source: Epocrates, 2019; Schrier, 2018

Table: CPT Codes / HCPCS Codes / ICD-10 Codes
Code Code Description

Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+" :

HCPCS codes covered if selection criteria are met:

J1303 Injection, ravulizumab-cwvz, 10 mg

ICD-10 codes covered if selection criteria are met:

D59.3 Hemolytic-uremic syndrome
D59.5 Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]

ICD-10 codes not covered for indications listed in the CPB:

D61.01 - D61.9 Other aplastic anemias and other bone marrow failure syndromes
G12.21 Amyotrophic lateral sclerosis
G36.0 Neuromyelitis optica [Devic]
G70.00 - G70.01 Myasthenia gravis

The above policy is based on the following references:

  1. Alexion Pharmaceuticals, Inc. Alexion received early FDA approval for Ultomiris (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Press Release. Boston, MA: Alexion Pharma; December 21, 2018a. Available at: https://news.alexion.com/press-release/product-news/alexion-receives-early-fda-approval-ultomiris-ravulizumab-cwvz-adults-par. Accessed December 28, 2018.
  2. Alexion Pharmaceuticals, Inc. Ultomiris (ravulizumab-cwvz) injection, for intravenous use. Prescribing Information. Boston, MA: Alexion Pharmaceuticals; revised October 2020.
  3. Alexion Pharmaceuticals, Inc. Ultomiris (ravulizumab-cwvz) injection, for intravenous use. Prescribing Information. Reference ID: 4367173. Boston, MA: Alexion Pharma; revised December 2018b.
  4. Alexion Pharmaceuticals, Inc. ALXN1210 versus eculizumab in complement inhibitor treatment-naïve adult patients with paroxysmal nocturnal hemoglobinuria (PNH). ClinicalTrials.gov Identifier: NCT02946463. Bethesda, MD: National Library of Medicine; updated February 14, 2018c.
  5. Alexion Pharmaceuticals, Inc.  ALXN1210 versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) currently treated with eculizumab. ClinicalTrials.gov Identifier: NCT03056040. Bethesda, MD: National Library of Medicine; updated March 26, 2018d.
  6. Alexion Pharmaceuticals, Inc. Alexion receives FDA approval for Ultomiris (ravulizumab-cwvz) for atypical hemolytic uremic syndrome (aHUS). Press Release. Boston, MA: Alexion Pharma; October 18, 2019a.
  7. Alexion Pharmaceuticals, Inc. Ultomiris (ravulizumab-cwvz) injection, for intravenous use. Prescribing Information. Boston, MA: Alexion Pharma; revised October 2019b.
  8. Besa EC. Paroxysmal nocturnal hemoglobinuria. Medscape. New York, NY: Medscape; updated December 23, 2018. Available at: https://emedicine.medscape.com/article/207468-overview. Accessed December 28, 2018.
  9. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010: 78: 211-230.
  10. Brodsky RA. Pathogenesis of paroxysmal nocturnal hemoglobinuria. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed November 2017a.
  11. Brodsky RA. Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed November 2017b.
  12. Brodsky RA. Treatment and prognosis of paroxysmal nocturnal hemoglobinuria. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed August 2018.
  13. Chen JJ. Overview of current and emerging therapies for amyotrophic lateral sclerosis. Am J Manag Care. 2020;26(9 Suppl):S191-S197.
  14. Duchow A, Chien C , Paul F , Bellmann-Strobl J. Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs. 2020;25(3):285-297.
  15. Epocrates. Aplastic anemia: Diagnostic criteria. Epocrates [online serial]. San Francisco, CA: Epocrates; 2019. Available at: https://online.epocrates.com/diseases/9636/Aplastic-anemia/Diagnostic-Criteria. Accessed January 2, 2019.
  16. Hillmen P. PNH and thrombosis: Who to treat and how. Medscape. New York, NY: Medscape. Available at: https://www.medscape.org/viewarticle/577318. Accessed January 2, 2019.
  17. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110(12):4123-4128.
  18. Ishiyama K, Nakao S, Usuki K, et al. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: Subgroup analysis of Japanese patients. Int J Hematol 2020;112(4):466-476.
  19. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study. Blood. 2019;133(6):540-549.
  20. Lee JW, Sicre de Fontbrune F, Wong LL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2019;133(6):530-539.
  21. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. Published online: April 11, 2015. 
  22. National Institutes of Health (NIH), National Library of Medicine (NLM). Paroxysmal nocturnal hemoglobinuria. Genetics Home Reference. Bethesda, MD: NIH; December 2018. Available at: https://ghr.nlm.nih.gov/condition/paroxysmal-nocturnal-hemoglobinuria#. Accessed December 28, 2018.
  23. National Institutes of Health (NIH), National Library of Medicine (NLM). Atypical hemolytic uremic syndrome. Genetics Home Reference [online]. Bethesda, MD: NIH; updated January, 23, 2017.
  24. National Organization for Rare Disorders (NORD). Paroxysmal nocturnal hemoglobinuria. Rare Disease Database. Danbury, CT; 2016. Available at: https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/. Accessed December 28, 2018.
  25. National Organization for Rare Disorders (NORD). Atypical hemolytic uremic syndrome. Rare Disease Database. Danbury, CT; 2016. Available at: https://rarediseases.org/rare-diseases/atypical-hemolytic-uremic-syndrome/. Accessed October 28, 2019.
  26. Parker CJ. Management of paroxysmal nocturnal hemoglobulinuria in the era of complement inhibitory therapy. Hematology. 2011; 21-29.
  27. Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One 2020;15(9): e0237497.
  28. Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol. 2014;89(3):339-341.
  29. Roth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: Results of 2 phase 1b/2 studies. Blood Advances. 2018;2:2176-2185.
  30. Schrier SL. Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed October 2017.
  31. Schrier SL. Treatment of aplastic anemia. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2018.
  32. Stern RM, Connell NT. Ravulizumab: A novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728. 
  33. U.S Food and Drug Administration (FDA). FDA approves new treatment for adult patients with rare, life-threatening blood disease. FDA News Release. Silver Spring, MD: FDA; December 21, 2018.